Supportive Oncology
Clinical positioning
Adjunctive supportive oncology product for symptom-burden, appetite, pain and quality-of-life conversations; not positioned as cancer-directed therapy.
Clinical use lens
Supportive oncology lensPosition only for symptom burden, appetite, pain, fatigue and quality-of-life discussion — not cancer-directed therapy.
Protocol mapping
Indication fit
Cancer-related fatigue
Pain burden
Appetite support
Quality of life
Why doctors reach for it
Clinical highlights
✦Oncology support: symptom-burden, pain, fatigue and appetite conversations
✓Quality of life: adjunctive supportive-care positioning only
→Rasayana logic: Guduchi, Shatavari, ghrita and Vijaya support recovery routines
How it is positioned to work
Mechanism map
1ECS-oriented pain, appetite and fatigue-support rationale
2Guduchi, Shatavari and ghrita-based rasayana logic for recovery support
3Supportive-care language only; not disease-modifying or anti-cancer treatment positioning
Physician-directed dosing
Administration & dosing
X
Dose framework
X = body weight in kilogramsFirst dose
≤ X/2 mgGrade-guided range
X–10X mg
≤ X/2 mgGrade-guided range
X–10X mg
First dose must never exceed X/2 mg total cannabinoids (equivalent to ≤0.5 mg/kg when X is body weight in kg). Further titration may move within X to 10X mg total cannabinoids only after tolerance and response review.
1–10
Indication grade
- Grade 1–10: set by indication severity, pain/inflammation burden, ESR, CRP and symptom trajectory.
- Adjust for age, frailty, secondary conditions, hepatic/renal risk, concurrent medicines and tolerance.
- Use follow-up response to hold, increase, reduce or discontinue.
↗
Titration model
- Incremental: gradual upward titration until response / tolerability.
- Incremental–decremental: step up, then reduce to minimum effective maintenance.
- Microdosing: very low divided exposure for sensitive, elderly or polypharmacy patients.
Rx
Administration
- Oral / sublingual / with suitable carrier as per physician direction and product format.
- Prefer consistent timing; document relation to food, sleep, pain peak, appetite or protocol goal.
- Document dose, route, time, food/carrier, indication grade, ESR/CRP or relevant markers, adverse effects and follow-up plan.
- Monitor sedation, dizziness, GI tolerance, cognition, drug interactions and functional response.
Full titration walkthrough: physician dosage guide.
In-clinic use
Doctor use notes & safety boundary
Doctor use notes
- Start low and titrate by clinical context, tolerability and symptom severity.
- Track response, co-medications, sedation, GI tolerance and follow-up outcome.
- Document dose, timing, duration, indication and review plan.
Safety boundary
- For registered medical practitioners only
- Select dose by clinical context and tolerability
- Monitor sedation, interactions and follow-up response
- Not for direct patient promotion
8 actives
Formula / ingredients
| Ingredient | Botanical / base | Part | Qty |
|---|---|---|---|
| Guduchi | Tinospora cordifolia | Stem | 8gm (8 %) |
| Bhallataka | Semecarpus anacardium | Seed | 0.8gm (0.8 %) |
| Shatavari | Asparagus racemosus | Roots | 0.4gm (0.4 %) |
| Bhandira | Clerodendron infortunatum | Roots | 0.4gm (0.4 %) |
| Lakshmitaru | Simarouba glauca | Leaf | 0.2gm (0.2 %) |
| Mahakanakasindhura | Bhasma preparation | — | 0.2gm (0.2 %) |
| Goghrita (Cow Ghee) | Cow’s ghee | — | 50gm (50 %) |
| Bhang (Vijaya) | Cannabis sativa Linn | Leaf | 40gm (40 %) |
Clinic packs
Pack / MRP
| Pack | Strength | MRP |
|---|---|---|
| 10 ml | 2000mg total cannabinoids≈ 10 mg/drop | ₹1,599 |
| 30 ml | 6000mg total cannabinoids≈ 10 mg/drop | ₹4,650 |
Pack / MRP summary: 10 ml ₹1,599 (2000mg) · 30 ml ₹4,650 (6000mg)
4 source links
Audited research links
| Audited reference fit | Clinical logic | Source |
|---|---|---|
| Cannabis / cannabinoids ✓ Boundary checkedNCBI / NCI boundaryClinical boundary Cannabis and Cannabinoids (PDQ®) — NCI/NCBI | Authoritative supportive-care / symptom-boundary reference; not cancer-directed treatment proof | Open ↗ |
| Cannabis / cannabinoids ✓ Boundary checkedNCBI / NCI boundaryClinical boundary Cancer — Health Effects of Cannabis and Cannabinoids | Cancer chapter boundary and supportive-care context | Open ↗ |
| Cannabis / cannabinoids ✓ Boundary checkedASCO guidelineClinical boundary ASCO Guideline | ASCO boundary: avoid cancer-directed treatment claims outside clinical trials | Open ↗ |
| Guduchi / Tinospora cordifolia ✓ Scientific fit checkedPubMed / PMIDScientific context Immunomodulatory active compounds from Tinospora cordifolia | Immunomodulatory active compounds / immune tone support | Open ↗ |
Educational use only. Doctor-facing scientific aid only. Research links are mapped for ingredient rationale, mechanism, clinical context and safety boundaries. This brochure does not replace diagnosis, standard-of-care treatment, regulatory prescribing rules or clinical monitoring. See our legal & medical disclaimer and editorial policy.
Same protocol
